Overview
- Several national plaintiff firms issued public notices on July 12–13 inviting investors who bought ADMA Biologics securities between August 9, 2024 and March 25, 2026 to join a pending securities class action and to move for lead‑plaintiff status by the August 10, 2026 deadline.
- The complaint, as described in the firms' notices, alleges an undisclosed related‑party transaction, deliberate channel stuffing to inflate reported revenue, and deficient internal controls that made public statements materially misleading.
- The suit asserts violations of Section 10(b) of the Exchange Act, Rule 10b‑5, and Section 20(a) for control‑person liability and seeks recovery for investors who lost money when the alleged problems were revealed.
- No class has been certified and the allegations remain unproven; investor notices are attorney advertising and potential class members are not represented by class counsel unless they retain counsel or a court appoints lead counsel.
- If appointed, a lead plaintiff would direct the litigation on behalf of the putative class and could affect strategy and settlement talks, while the competing firm outreach reflects routine contest for lead roles rather than a judgment on ADMA's conduct.